Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas

(2012) Efthimia Souka et al.   HISTOPATHOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

(2012) Sae-Won Han et al.   PLoS One

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

(2011) A Ålgars et al.   BRITISH JOURNAL OF CANCER

Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations

(2011) Ning Lv et al.   Diagnostic Pathology

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas

(2011) Balázs Szabó et al.   ORAL ONCOLOGY

EGFR expression and gene copy number in triple-negative breast carcinoma

(2010) Berrak Gumuskaya et al.   CANCER GENETICS AND CYTOGENETICS

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

(2009) Francisco J. Esteva et al.   Nature Reviews Clinical Oncology

Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers

(2008) Tatsuya Toyama et al.   BMC CANCER

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

(2008) F Cappuzzo et al.   BRITISH JOURNAL OF CANCER

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review

(2008) Yolanda Madarnas et al.   CANCER TREATMENT REVIEWS

HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

(2008) M. F. Press et al.   CLINICAL CANCER RESEARCH

HER-2-positive metastatic breast cancer: trastuzumab and beyond

(2008) Giulio Metro et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

(2008) J. A. Gilbert et al.   MOLECULAR CANCER THERAPEUTICS